X4 Pharmaceuticals (X4 Pharmaceuticals) Interest Expense : $-6.54 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is X4 Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. X4 Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ -1.87 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.54 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. X4 Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -37.29 Mil. X4 Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ -1.87 Mil. X4 Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

X4 Pharmaceuticals Interest Expense Historical Data

The historical data trend for X4 Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals Interest Expense Chart

X4 Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.15

-2.69

-3.64

-3.99

-5.78

X4 Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-1.11	-1.15	-1.63	-1.89	-1.87

X4 Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.54 Mil.

X4 Pharmaceuticals (NAS:XFOR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

X4 Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $-1.87 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-37.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $57.14 Mil.

X4 Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

X4 Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

X4 Pharmaceuticals (X4 Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (NAS:XFOR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

48Q:Germany

Address

61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134

Website

https://www.x4pharma.com

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.

Executives

Paula Ragan	director, officer: President and CEO	C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVE., 4TH FLOOR, CAMBRIDGE MA 02139
Mark Baldry	officer: Chief Commercial Officer	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arthur Taveras	officer: Chief Scientific Officer	C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Mary Dibiase	officer: Chief Operating Officer	61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Adam S. Mostafa	officer: See Remarks	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Keith Woods	director	C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON MA 02134
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Christophe Arbet-engels	officer: Chief Medical Officer	C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Murray Stewart	director	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Craecker Francoise De	director	61 NORTH BEACON STREET, 4TH FLOOR, BOSTON MA 02134
Derek M Meisner	officer: General Counsel	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Diego Cadavid	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alison Frances Lawton	director	39 ROBINSON ROAD, LEXINGTON MA 02420
Renato Skerlj	officer: Chief Scientific Officer	C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIGE MA 02139
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949